Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Cancer stem cells (CSCs) are a rare population with self-renewal and multipotent differentiation capacity, and reside among the more differentiated cancer cells. CSCs are associated with tumor recurrence, drug resistance...
Saved in:
Main Authors: | Ya Li (Author), Qiuju Han (Author), Huajun Zhao (Author), Quanjuan Guo (Author), Jian Zhang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
by: Takuji Okusaka, et al.
Published: (2023) -
Inhibitory effect of napabucasin on arbidol metabolism and its mechanism research
by: Jingjing Nie, et al.
Published: (2023) -
A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma
by: Ye-Bin Pang, et al.
Published: (2019) -
Recent advances in systemic therapy for hepatocellular carcinoma
by: Huajun Zhang, et al.
Published: (2022) -
The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma
by: Yan Xiang, et al.
Published: (2016)